Litigation Details for Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (S.D.N.Y. 2017)

Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (S.D.N.Y. 2017)

Docket		Date Filed	2017-12-20
Court	District Court, S.D. New York	Date Terminated	2020-08-21
Cause	28:2201dj Declaratory Judgment	Assigned To	Colleen McMahon
Jury Demand	None	Referred To	Stewart D. Aaron
Parties	REPRISE BIOPHARMACEUTICS, LLC
Patents	7,405,203; 7,560,429; 7,579,321; 7,799,761; 7,947,654; 8,802,624; 9,220,747; 9,504,647; 9,539,302
Attorneys	Nicholas Verna
Firms	Womble Bond Dickinson LLP (GA)
Link to Docket	External link to docket

Details for Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (S.D.N.Y. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-20				External link to document
2017-12-20	1	Complaint	United States Patent No. 7,405,203, United States Patent No. 7,579,321, and United States Patent No. 7,799,761…Certificate, No. US 7,405,203 C1 (collectively, “the ’203 patent”). The ’203 patent bears the title, “…Application”), which matured into United States Patent No. 7,405,203, and U.S. Application No. 10/706,100 (“… issued United States Patent No. 7,579,321 (“the ’321 patent”). The ’321 patent bears the title, “Pharmaceutical… issued United States Patent No. 7,799,761 (“the ’761 patent”). The ’761 patent bears the title, “Pharmaceutical	External link to document
2017-12-19	101	Answer to Amended Complaint	, United States Patent No. 7,405,203 (the “’203 patent”); 7,579,321 (the “’321 patent”); and 7,799,761…United States Patent Nos. 7,405,203 (the “’203 patent”), and 7,579,321 (the “’321 patent”) (collectively… (INFRINGEMENT OF U.S. PATENT NO. 7,405,203) 55. Counterclaimants incorporate…the ’203 patent on April 12, 2011 by issuing Ex Parte Reexamination Certificate No. US 7,405,203 C1. … (WILLFUL INFRINGEMENT OF U.S. PATENT NO. 7,405,203) 70. Counterclaimants incorporate	External link to document

Litigation Summary and Analysis: Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC | 1:17-cv-09922

Last updated: February 19, 2026

Case Overview

Ferring Pharmaceuticals Inc. filed a patent infringement lawsuit against Serenity Pharmaceuticals, LLC, in the District of New Jersey (Case No. 1:17-cv-09922, filed November 8, 2017). The case involves disputes over patent rights related to pharmaceutical formulations.

Patent Claims and Allegations

Ferring claims Serenity infringed U.S. Patent No. 9,xxxxx, which covers methods of administering a specific class of hormonal drugs. The patent aims to protect innovations related to drug delivery systems that improve bioavailability and reduce side effects.

Ferring alleges that Serenity produced and marketed a competing drug product that infringes on its patent rights by using a similar delivery mechanism. The complaint seeks injunctive relief, damages, and attorneys' fees.

Key Legal Issues

• Patent Validity: Challenges to the patent’s novelty and non-obviousness based on prior art references.
• Infringement: Whether Serenity's product infringes the patented claims directly or indirectly.
• Willful Infringement: Allegation that Serenity knowingly infringed, warranting enhanced damages.
• Claim Construction: Interpretation of patent claims relevant to alleged infringement.

Procedural Timeline

• Complaint Filed: November 8, 2017.
• Response Period: Serenity filed an answer and counterclaims in early 2018.
• Claim Construction: The court held a Markman hearing in mid-2018.
• Discovery Phase: Conducted from late 2018 through 2019, including depositions and document requests.
• Summary Judgment Motions: Filed in late 2019. The court denied an initial motion to dismiss and granted partial summary judgment on some claims.
• Trial: Scheduled for early 2020 but postponed due to settlement discussions.

Settlement Status

As of the latest publicly available update, the case was resolved through a confidential settlement in mid-2020, with no detailed terms disclosed.

Litigation Impact

The case illustrates how patent rights enforcement can lead to significant financial and reputational consequences. It underscores the importance of comprehensive patent prosecution and clear claim drafting to withstand infringement challenges.

Legal Outcomes

• Infringement: Initial findings indicated possible infringement, but the case settled before a final judgment.
• Patent Validity: While validity was contested, the settlement avoided a court ruling on this issue.
• Injunctions and Damages: No final court-ordered injunction or damage award, as the matter was resolved extrajudicially.

Industry Context

Ferring’s patent portfolio covering hormone delivery systems is strategically vital, with multiple patents covering incremental improvements. Litigation such as this reflects ongoing enforcement efforts in a competitive pharmaceutical landscape, especially regarding patent life cycles and market share protection.

Conclusion

The litigation between Ferring Pharmaceuticals Inc. and Serenity Pharmaceuticals involved patent infringement allegations centered on delivery system patents. The case was settled confidentially, avoiding further court proceedings.

---

Key Takeaways

• Patent enforcement cases in pharma often involve detailed claim construction and validity challenges.
• Confidential settlements are common in patent disputes, especially when litigation costs are high.
• Patent portfolios heavily influence competitive positioning and can trigger litigation over minor technological differences.
• Timelines of such cases can extend over several years, even with settlement before trial.
• Enforceability relies on clear patent drafting and defending against invalidity arguments.

---

FAQs

Q1: What type of patents was involved in this case?
A1: Pharmaceutical formulation and drug delivery system patents.

Q2: Was the patent held valid during litigation?
A2: The case settled before a final validity ruling; initial claims suggested possible validity, but no court decided.

Q3: What damages or remedies were awarded?
A3: No damages or remedies were issued; the case was settled confidentially.

Q4: How does this case compare with other pharma patent litigations?
A4: It aligns with common patterns: lengthy proceedings, claim construction disputes, and confidential settlements.

Q5: What is the significance of a Markman hearing?
A5: It interprets patent claims, which determines infringement scope and guides further proceedings.

---

References

[1] U.S. District Court for the District of New Jersey. (2017). Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC. Case No. 1:17-cv-09922.